A comparative study to evaluate the efficacy and safety of twice daily versus alternate day oral iron therapy in treatment of mild to moderate iron deficiency anemia in adults - an open label, randomized controlled study - NI

Viswanathan S0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年4月1日

试验速览

暂无简介。

•1. Patient willing to give written informed consent and willing to come for follow-up
•2. Adults 18-60 years of age of either sex
•3. Patients newly diagnosed as mild to moderate iron deficiency anemia by WHO guidelines

•1. Patients having comorbidities like chronic kidney disease, chronic liver disease, severe anemia requiring blood transfusion/parenteral iron therapy, cardiac failure patients, gastrointestinal abnormalities, menstrual abnormalities, malignancies and HIV
•2. Pregnant and Lactating mothers
•3. Patients with clinical or laboratory evidence of other causes of anemia like hemolytic anemias, hemoglobinopathies, gastrointestinal bleed, iron malabsorption, megaloblastic anemia, or anemia of chronic disease
•4.Patients with hypersensitivity and intolerance to oral iron supplements.

发起方

Viswanathan S